147 related articles for article (PubMed ID: 35199379)
1. Psoriasiform dermatitis in a girl with ulcerative colitis receiving vedolizumab.
Tsuchiya M; Hashimoto R; Arai K; Yoshida K
J Dermatol; 2022 Jun; 49(6):e191-e192. PubMed ID: 35199379
[No Abstract] [Full Text] [Related]
2. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
3. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
4. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
5. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
7. Acute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab.
Lin E; Katz S
Inflamm Bowel Dis; 2020 Apr; 26(5):e44. PubMed ID: 32100867
[No Abstract] [Full Text] [Related]
8. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
Hinojosa Del Val J; Barreiro-de Acosta M
Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.
de Freitas LF; Feitosa MR; Féres O; Parra RS
Inflamm Bowel Dis; 2021 Jan; 27(2):e15-e17. PubMed ID: 33048114
[No Abstract] [Full Text] [Related]
10. Herpes Zoster in a Patient With Ulcerative Colitis After Vedolizumab Initiation-Causal Link or Only Temporal Coincidence?
Wu N; Li H; Zhang J; Huang W
Inflamm Bowel Dis; 2022 Feb; 28(2):e22-e23. PubMed ID: 34480561
[No Abstract] [Full Text] [Related]
11. Acneiform eruption induced by vedolizumab.
Magdaleno-Tapial J; Ferrer-Guillén B; Valenzuela-Oñate C; Esteve-Martínez A
Dermatol Online J; 2018 Oct; 24(10):. PubMed ID: 30677821
[TBL] [Abstract][Full Text] [Related]
12. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
13. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
Battat R; Ma C; Jairath V; Khanna R; Feagan BG
Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
[TBL] [Abstract][Full Text] [Related]
14. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab.
Zimmerman LA; Zalieckas JM; Shamberger RC; Bousvaros A
J Pediatr Surg; 2018 Jul; 53(7):1330-1333. PubMed ID: 29370898
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab: first global approval.
Poole RM
Drugs; 2014 Jul; 74(11):1293-303. PubMed ID: 24985716
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K
Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861
[TBL] [Abstract][Full Text] [Related]
18. Late onset vedolizumab-induced eosinophilic pneumonia in a patient with ulcerative colitis.
Faria LM; Oliveira MM; Faria AA; Vasconcellos AVO; Cançado GGL
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):513-514. PubMed ID: 36827537
[No Abstract] [Full Text] [Related]
19. Excipient Exception: A Complication of Infliximab and Vedolizumab Infusions for Ulcerative Colitis.
Dalal RS; Goksel B; Hamilton MJ
Dig Dis Sci; 2023 May; 68(5):1709-1713. PubMed ID: 36929242
[No Abstract] [Full Text] [Related]
20. Hidradenitis Suppurativa Caused by Vedolizumab.
Licata G; Gambardella A; De Rosa A; Calabrese G; Alfano R; Argenziano G
Dermatitis; 2021 Jan-Feb 01; 32(1):e23-e24. PubMed ID: 33208632
[No Abstract] [Full Text] [Related]
[Next] [New Search]
